Olema reports Phase 1b/2 data for OP-1250 + palbociclib in ER+/HER2- mBC

Olema Pharmaceuticals, Inc.

Combination of OP-1250 (up to 120 mg) with palbociclib 125 mg was safe and well-tolerated in 29 patients, with no DDI.
No dose-related increases in adverse events; neutropenia consistent with palbociclib plus endocrine therapy profile.
Partial responses observed in 5 patients (1 confirmed, 4 unconfirmed); clinical benefit rate 42% (5/12 CBR-eligible).
59% of patients remain on treatment as of March 8, 2023 data cut-off; enrollment ongoing toward ~45 patients.
OP-1250 showed favorable PK: 8-day half-life, dose-proportional exposure, no effect on palbociclib levels.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.